Clearmind Medicine (CMND) Stock Doubles as CMND-100 Passes Critical Safety Milestone

Key Takeaways CMND-100 successfully achieved its primary safety endpoint in a Phase I/IIa trial targeting Alcohol Use Disorder No serious adverse events occurred in the third cohort, demonstrating robust safety even at elevated dose levels Shares of CMND surged more than 100%, reaching approximately $1.44 following the announcement The multinational study has FDA approval and is assessing safety, tolerability, and preliminary efficacy in patients with moderate to severe AUD Following safety data review, the Data and Safety Monitoring Board greenlit trial continuation Shares of Clearmind Medicine (CMND) experienced a dramatic surge on Monday, climbing more than 100% after the biotechnology company revealed positive results from its Phase I/IIa clinical trial evaluating CMND-100 for Alcohol Use Disorder treatment. Clearmind Medicine Inc., CMND At the time of reporting, CMND was changing hands near $1.44, representing approximately a 100% gain for the session. Data from the trial’s third cohort demonstrated encouraging safety and tolerability characteristics, particularly noteworthy given that participants received the highest dosage levels examined thus far. The study reported zero serious adverse events. According to the company, these findings mirror results from previous cohorts, indicating that CMND-100 maintains its favorable safety characteristics as dosing escalates. CMND-100 represents a non-hallucinogenic therapeutic candidate based on MEAI, administered orally. The compound is being pursued as a potential treatment for individuals suffering from moderate to severe Alcohol Use Disorder. The ongoing Phase I/IIa investigation is a multinational, multicenter clinical effort. Researchers are examining safety parameters, tolerability metrics, pharmacokinetic properties, and initial efficacy signals. Significant Regulatory Progress Achieving the primary safety endpoint during the dose-escalation phase represents meaningful progress for the development program. A...